FirsthandHealth
medRxiv PreprintsInternational17 November 2026

Plasma Proteomic Identifies GDF15 as a Candidate Lithium Treatment Response Biomarker in Mild Cognitive Impairment: A Secondary Analysis of the LATTICE Randomized Clinical Trial

This is an official announcement record

Firsthand records what medRxiv Preprints announced and links to the original. The wording below is theirs, not ours.

Lithium (Li) demonstrates neuroprotective effects relevant to Alzheimer disease (AD). However, its molecular mechanisms remain insufficiently characterized. This study analyzed plasma proteomic profiles from the Li as a Treatment to Prevent Impairment of Cognition in Elders (LATTICE) randomized clinical trial to identify markers associated with amyloid beta pathology, disease progression, and response to Li treatment. In the LATTICE trial, 80 older adults with mild cognitive impairment (MCI) were randomly assigned to receive either low-dose Li carbonate or placebo for two years. Longitudinal p
Source: medRxiv Preprints
Read the official announcement

Opens www.medrxiv.org

More from medRxiv Preprints

This content is for informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any supplement, treatment, or program: especially if you are pregnant, nursing, taking medication, or managing a health condition.